Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Frequently asked questions
What sector does Eterna Therapeutics Inc (ERNA) operate in?
Eterna Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Eterna Therapeutics Inc (ERNA) current stock price?
As of the latest data, Eterna Therapeutics Inc stock price is $4.86, with a previous close of $4.62. Eterna Therapeutics Inc gained $0.24 in the last trading session, representing a 5.31% increase.
What is Eterna Therapeutics Inc (ERNA) current market capitalization?
Eterna Therapeutics Inc market cap is approximately 5.67 million.
What is Eterna Therapeutics Inc (ERNA) Earnings Per Share (EPS)?
The trailing EPS is -$0.41, and the forward EPS is -$1.86.
What is Eterna Therapeutics Inc (ERNA) EBITDA?
Eterna Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.01 million.
Does Eterna Therapeutics Inc (ERNA) pay dividends?
No. Eterna Therapeutics Inc does not pay a dividend.
What is Eterna Therapeutics Inc (ERNA) beta (volatility) score?
Eterna Therapeutics Inc has a beta of 2.562, indicating very high volatility compared to the market.
